Myasthenia gravis as a prototype autoimmune receptor disease

Immunologic Research

Volumn 16, Issue 4, 1997, Pages 341-354

  Hoedemaekers, Astrid C W E ^a   Van Breda Vriesman, Peter J C ^a   De Baets, Marc H ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Acetylcholine receptor; Auto antibodies; Autoimmunity; Experimental autoimmune myasthenia gravis; Myasthenia gravis; Susceptibility; Target organ

Indexed keywords

AUTOANTIBODY; NICOTINIC RECEPTOR;

AUTOIMMUNE DISEASE; DISEASE PREDISPOSITION; DISEASE SEVERITY; HUMAN; IMMUNOPATHOGENESIS; MYASTHENIA GRAVIS; NEUROTRANSMISSION; NONHUMAN; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; REVIEW; TARGET ORGAN;

EID: 0031441479     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02786398     Document Type: Review

References (131)

1. Slater C, Vincent A: Structure and development of the neuromuscular junction; in Vincent A, Wray D, eds.): Neuromuscular Transmission. Basic and Applied Aspects. Manchester, UK, Manchester University Press, 1990.
2. Jennekens F, Veldman H, Wokke J: Histology and pathology of the human neuromuscular junction with a description of the clinical features of the myasthenic syndromes; in De Baets M, Oosterhuis H, (eds.): Myastheniagravis. Boca Raton, FL CRC, 1993, 99-145.
3. Gu Y, Hall Z: Characterization of acetylcholine receptor subunits in developing and in denervated mammalian muscle. J Biol Chem 1988;263:12,878-12,885.
4. Trautmann A: Curare can ope and block ionic channels associated with cholinergic receptors. Nature 1982;298:272-275.
5. Schuetze S: Embryonic and adult acetylcholine receptors: molecular basis of developmental changes in ion channnel properties. Trends Neurosci 1986;9:386-388.
6. Mishina M, Takai T, Imoto K, Noda M, Takahashi T, Numa S, Methfessel C, Sakmann B: Molecular distinction between fetal and adult forms of muscle acetylcholine receptor. Nature 1986;321:406-411.
7. Gu Y, Franco A, Gardner P, Lansmann J, Forsayeth J, Hall Z: Properties of embryonic and adult muscle acetylcholine receptors transiently expressed in COS cells. Neuron 1990;5:147-157.
8. Hall Z, Gorin P, Silberstein L, Bennet C: A postnatal change in the immunological properties of the acetylcholine receptor at rat muscle endplates. J Neurosci 1985;5:730-734.
9. Strader C, Revel J-P , Raftery M: Demonstration of the transmembrane nature of the acetylcholine receptor by labeling with anti-receptor antibodies. J Cell Biol 1979;83:499-510.
10. Lindstrom J, Shelton D , Fujii Y: Myasthenia Gravis. Adv Immunol 1988;42:233-284.
11. Changeux J-P: Compartimentalized transcription of acetylcholine receptor genes during motor endplate epigenesis. New Biol 1991;3:413-429.
12. Duclert A, Changeux J-P: Acetylcholine receptor gene expression at the developing neuromuscular junction. Physiol Rev 1995;75: 339-368.
13. Fontaine B, Sassoon D, Buckingham M, Changeux J-P: Detection of the nicotinic acetylcholine receptor α-subunit mRNA by in situ hybridization at neuromuscular junctions of 15-day-old chick straited muscles. EMBO J 1988;7:603-609.
14. Fontaine B, Changeux J-P: Localization of nicotinic acetylcholine receptor α-subunit transcripts during myogenesis and motor endplate development in the chick. J Cell Biol 1989;108:1025-1037.
15. Kues W, Sakmann B, Witzemann V: Differential expression patterns of five acetylcholine receptor subunit genes in rat muscle during development. Eur J Neurosci 1995;7:1376-1385.
16. Pavlath G, Rich K, Webster S, Blau H: Localization of muscle gene products in nuclear domains. Nature 1989;337:570-573.
17. Ralston E, Hall Z: Transfer of a protein encoded by a single nucleus to nearby nuclei in multinucleated myotubes. Science 1989;244: 1066-1069.
18. Fontaine B, Klarsfeld A, Hokfelt T, Changeux J-P: Calcitonin gene-related peptide, a peptide present in spinal cord motoneurons, increases the number of acetylcholine receptors in primary cultures of chick embryo myotubes. Neurosci Lett 1986;71:59-65.
19. Usdin T, Fischbach G: Purification and characterization of a polypeptide from chick brain that promotes the accumulation of acetylcholine receptors in chick myotubes. J Cell Biol 1986;103:493-507.
20. Altiok N, Bessereau J-L, Changeux J-P: ErbB3 and ErbB2/neu mediate the effect of heregulin on acetylcholine receptor gene expression in muscle: differential expression at the endplate. EMBO J 1995;14:4258-4266.
21. Bessereau J-L, Stratford-Perricaudet LD, Piette J, La Poupon C, Changeux J-P: In vivo and in vitro analysis of electrical activity-dependent expression of muscle acetylcholine recptor genes using adenovirus. Proc Natl Acad Sci USA 1994;91:1304-1308.
22. Piette J, Bessereau J-L, Huchet M, Changeux J-P: Two adjacent MyoDl-binding sites regulate expression of the acetylcholine receptor α-subunit gene. Nature 1990;345:353-355.
23. Weintraub H: The MyoD family and myogenesis: redundancy, networks and thresholds. Cell 1993; 75:1241-1244.
24. Buckingham M: Molecular biology of muscle development. Cell 1994; 78:15-21.
25. Venuti J, Morris J, Vivian J, Olson E, Klein W: Myogenin is required for late but not early aspects of myogenesis during mouse development. J Cell Biol 1995;128:563-567.
26. Duclert A, Savatier N , Changeux J-P: An 83-nucleotide promotor of the acetylcholine ε-subunit gene confers preferential synaptic expression in mouse muscle. Proc Natl Acad Sci USA 1993;90: 3043-3047.
27. Duclert A, Savatier N, Schaeffer L, Changuex J-P: Identification of an element crucial for the subsynaptic expression of the acetylcholine receptor ε-subunit gene. J Biol Chem 1996;271: 17,433-17,438.
28. Koike S, Schaeffer L, Changeux J-P: Identification of a DNA element determining synaptic expression of the mouse acetylcholine receptor δ-subunit gene. Proc Natl Acad Sci USA 1995;92:10,624-10,628.
29. Lennon V, Lindstrom J , Seybold M: Experimental autoimmune myasthenia: a model of myasthenia gravis in rats and guinea pigs. J Exp Med 1975;141:1365-1375.
30. Drachman D: How to recognize an antibody-mediated autoimmune disease: criteria; in Waksman B (ed): Immunologic Mechanisms in Neurologic and Psychiatric Disease, New York: Raven, 1990, pp. 183-186.
31. Lindstrom J, Seybold M, Lennon V, Whittingham S, Duane D: Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates and diagnostic value. Neurology 1976;26:1054-1059.
32. Toyka KV, Drachman DB,Pestronk A, Koa I: Myasthenia Gravis: passive transfer from man to mouse. Science 1975;190:397-399.
33. Patrick J, Lindstrom J: Autoimmune response to acetylcholine receptor. Science 1973;180:871-872.
34. Dau P: Response to plasmapheresis and immunosuppressive drug therapy in sixty myasthenia gravis patients. Ann NY Acad Sci 1981; 377:700-770.
35. Newsom-Davis J. Vincent A, Wilson S, Ward C: Long-term effects of repeated plasma exchange in myasthenia gravis. Lancet 1979;i:464-468.
36. Kuks J, Oosterhuis H, Limburg P, The T: Anti-acetylcholine receptor antibodies decrease after thymectomy in patients with myasthenia gravis. Clinical correlations. J Autoimmun 1991;4:197-211.
37. Oosterhuis H: Clinical aspects; in: De Baets M, Oosterhuis H (eds.): Myasthenia Gravis. Boca Raton, FL, CRC, 1993.
38. Osserman K, Genkins G: Studies in myasthenia gravis: Review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 1971;38:497-537.
39. Oosterhuis H: Studies in myasthenia gravis. Part I. A clinical study of 180 patients. J Neurol Sci 1964;1:512-546.
40. Lindstrom J, Einarson B, Lennon V, Seybold M: Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental autoimmune myasthenia gravis. J Exp Med 1976;144:726-738.
41. Einarson B, Gullick W, Conti-Tronconi B, Ellisman M, Lindstrom J: Subunit composition of bovine muscle acetylcholine receptor. Biochemistry 1982;21:5295-5302.
42. Scadding G, Calder L, Vincent A, Prior C, Wray D: Anti-acetylcholine receptor antibodies induced in mice by syngeneic receptor without adjuvants. Immunology 1986;58: 151-155.
43. Lindstrom J, Einarson B , Merlie J: Immunization of rats with polypeptide chains from torpedo acetylcholine receptor causes an autoimmune response to receptors in rat muscle. Proc Natl Acad Sci USA 1978;75:769-773.
44. Lennon V, McCormick D, Lambert E, Griesmann G, Zouhair Atassi M: Region of peptide 125-147 of acetylcholine receptor a subunit is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis, T cell immunity and modulating auto-antibodies. Proc Natl Acad Sci USA 1985;82:8805-8809.
45. Takamori M, Okumura S, Nagata M, Yoshikawa H: Myasthenogenic significance of synthetic a-subunit peptide 183-200 of Torpedo californica and human acetylcholine receptor. J Neurol Sci 1988;85: 121-129.
46. Lennon V, Lambert E, Leiby K, Okarma T, Talib S: Recombinant human acetylcholine receptor α-subunit induces chronic experimental autoimmune myasthenia gravis. J Immunol 1991;146: 2245-2248.
47. Gu D, Wogensen L, Calcutt N, Xia C, Zhu S, Merlie J, Fox H, Lindstrom J, Powell H, Sarvetnick N: Myasthenia gravis-like syndrome induced by expression of Interferon γ in the neuromuscular junction. J Exp Med 1995;181: 547-557.
48. Richman D, Gomez C, Berman P, Burres S, Fitch F, Arnason B: Monoclonal anti-acetylcholine receptor antibodies can cause experimental myasthenia. Nature 1980;286:738-739.
49. Lennon V, Lambert E: Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors. Nature 1980; 285:238-240.
50. Lindstrom J, Engel A, Seybold M, Lennon V, Lambert E: Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies. J Exp Med 1976;144: 739-753.
51. Tzartos S, Hochschwender S, Vasquez P, Linstrom E: Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor. J Neuroimmunol 1987;15:185-194.
52. Gomez C, Wollmann R , Richman D: Induction of the morphologic changes of both acute and chronic experimental autoimmune myasthenia by monoclonal antibody directed against acetylcholine receptor. Acta Neuropathol 1984; 63:131-143.
53. Tarrab-Hazdai R, Aharonov A, Silman I, Fuchs S: Experimental autoimmune myasthenia induced in monkeys by purified acetylcholine receptor. Nature 1975;256:128-130.
54. Berman P, Patrick J: Experimental myastenia gravis. A murine system. J Exp Med 1980;151:204-233.
55. Biesecker G, Koffler D: Resistance to experimental autoimmune Myasthenia Gravis in genetically inbred rats. J Immunol 1988;140:3406-3410.
56. Fuchs S, Nevo D, Tarrab-Hazdai R: Strain differences in the autoimmune response of mice to acetylcholine receptors. Nature 1976; 263:329, 330.
57. Berman P, Patrick J: Linkage between the frequency of muscular weakness and loci that regulate immune responsiveness in murine experimental autoimmune myasthenia gravis. J Exp Med 1980; 152:507-520.
58. Christadoss P: Immunogenetics of experimental autoimmune myasthenia gravis. Crit Revs Immunol 1989;9:247-278.
59. Christadoss P, Shenoy M: Molecular immunopathogenesis of experimental autoimmune myasthenia gravis. Reg Immunol 1994;4:314-320.
60. Marzo A, Garlepp M, Schon-Hegrad M, Dawkins RL: Susceptibility to murine experimental autoallergic myasthenia gravis: the role of antibody specificity. Clin Exp Immunol 1986;64:101-106.
61. Graus Y, Verschuuren J, Spaans F, Jennekens F, van Breda Vriesman PJC, De Baets MH: Age-related resistance to experimental autoimmune Myasthenia Gravis in rats. J Immunol 1993;150:4093-4103.
62. Hoedemaekers A, Graus Y, van Breda Vriesman P, De Baets M: Age-and sex-related resistance to experimental autoimmune myasthenia gravis in Brown Norway rats. Clin Exp Immunol 1997; 107:189-197.
63. Hoedemaekers A, Graus Y, Beijleveld L, VanBreda Vriesman P, De Baets M: Macrophage infiltration at the neuromuscular junction does not contribute to AChR loss and age-related resistance to EAMG. J Neuroimmunol 1997; 75:147-155.
64. Hoedemaekers A, Graus Y, Vroomen M, van Breda Vriesman P, De Baets M: Age-and sex-related resistance to experimental autoimmune myasthenia gravis in BN rats. J Neuroimmunol 1994; 54:168-W09.02.
65. Roubinian R, Talal N, Greenspan J, Goodman J, Siiteri P: Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerolunephritis in NZB/NZW F1 mice. J Exp Med 1978;147:1568-1583.
66. Melez K, Boegel W, Steinberg A: Therapeutic studies in New Zealand mice. VII. Successful androgen treatment of NZB/NZW F1 females of different age. Arthritis Rheumatism 1980;23:41-47.
67. Verheul H, Stimson W, Den Hollander F, Shuurs A: The effects of nandrolon, testoterone and their decanoate esters on murine lupus. Clin Exp Immunol 1981;44:11-17.
68. De Baets M, Verschuuren J, Daha M, van Breda Vriesman P: Effects of the rate of acetylcholine receptor synthesis on the severity of experimental autoimmune myasthenia gravis. Immunol Res 1988; 7:200-211.
69. Drachman B: Myasthenia gravis. N Engl J Med 1994;330:1797-1810.
70. Vincent A, Li Z, Hart A, Barrett-Jolley R, Yamamoto T, Burges J, Wray D, Byrne N, Molenaar P, Newsom-Davis J: Seronegative myasthenia gravis. Evidence for plasma factor(s) interfering with acetylcholine receptor function. Ann NY Acad Sci 1993;681:529-538.
71. Mossman S, Vincent A. Newsom-Davis J: Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity. Lancet 1986;140:116-118.
72. Drachman D, Angus C, Adams R, Michelson JD, Huffman GJ: Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med 1978; 298:1116-1122.
73. Tzartos S, Sophianos D, Zimmerman K, Starzinski-Powitz A: Antigenic modulation of human myotube acetylcholine receptor by myasthenic sera. Serum titer determines receptor internalization rate. J Immunol 1986;136:3231-3238.
74. Tzartos S, Seybold M , Lindstrom J: Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc Natl Acad Sci USA 1982;79:188-192.
75. Sophianos D. Tzartos S: Fab fragments of monoclonal antibodies protect the human acetylcholine receptor against antigenic modulation caused by myasthenic sera. J Autoimmunity 1989;2:1-13.
76. Loutrari L, Kokla A, Tzartos SJ: Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor. Eur J Immunol 1992;22:2449-2452.
77. Vincent A, Whiting P, Schluep M, Heindenreich F, Lang B, Roberts A, Wilcox N, Newsom-Davis J: Antibody heterogeneity and specificity in myasthenia gravis. Ann NY Acad Sci 1987;505:106-120.
78. Engel A, Lambert E , Howard F: Immune complexes (IgG and C3) at the motor endplate in myasthenia gravis. Mayo Clin Proc 1977;52:267-280.
79. Lennon V, Seybold M, Lindstrom J, Cochrane C, Ulevitch R: Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med 1978; 147:973-983.
80. Biesecker G, Gomez C: Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J Immunol 1989; 142:2654-2659.
81. Christadoss P: C5 gene influences the development of murine myasthenia gravis. J Immunol 1988; 140:2589-2592.
82. Lang B, Richardson G, Rees J, Vincent A, Newsom-Davis J: Plasma from myasthenia gravis patients reduces acetylcholine receptor agonist-induced Na+ flux into TE671 cell line. J Neuroimmunol 1988;19:141-148.
83. Graus Y, van Breda Vriesman P, De Baets M: Characterization of anti-acetylcholine receptor (AChR) antibodies from mice differing in susceptibility for experimental autoimmune myasthenia gravis. Clin Exp Immunol 1993;92:506-513.
84. Mygland A, Tysnes O-B, Aarli J, Flood P, Gilhus N: Myasthenia gravis patients with thymoma have antibodies against a high molecular weight protein in sarcoplasmic reticulum. J Neuroimmunol 1992;37:1-7.
85. Christadoss P , Dauphinee M: Immunotherapy for myasthenia gravis: a murine model. J Immunol 1986;136:2437-2440.
86. Kaul R, Shenoy M, Goluszko E, Christadoss P: Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. J Immunol 1994;152:3152-3157.
87. Zhang G, Ma C, Xiao B, Bakhiet M, Link H, OlssonT: Depletion of CD8+ T cells suppresses the development of experimental autoimmune myasthenia gravis in Lewis rats. Eur J Immunol 1995; 25:1191-1198.
88. Zhang G, Xiao B, Bakhiet M, van der Meide P, Wigzell H, Link H, Olsson T: Both CD4+ and CD8+ cells are essential to induce experimental autoimmune myasthenia gravis. J Exp Med 1996; 184:349-356.
89. Link J, Soderstrom M, Ljungdahl A, Hojeberg B, Olsson T, Xu Z, Frederikson S, Wang Z-H, Link H: Organ-specific autoantigens induce interferon-γ and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Neurology 1994;44:728-734.
90. De Baets M, Einarson B, Lindstrom J, Weigle W: Lymphocyte activation in experimental autoimmune myasthenia gravis. J Immunol 1982;128:2228-2235.
91. Fujii Y , Lindstrom J: Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. response to subunits and synthetic peptides. J Immunol 1988;140:1830-1837.
92. Hohlfeld R, Toyka K, Tzartos S, Carson W, Conti-Tronconi B: Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor α subunit. Proc Natl Acad Sci USA 1987;84:5379-5383.
93. Newsom-Davis J, Harcourt G, Sommer N, Beeson D, Willcox N, Rothbard J: T-cell reactivity in myasthenia gravis. J Autoimmunity 1989;2(Suppl):101-108.
94. Zhang Y, Schluep M, Frutiger S, Hughes G, Jeannet M, Steck A, Barkas T: Immunological heterogeneity of autoreactive T lymphocytes against the nicotinic acetylcholine receptor in myasthenic patients. Eur J Immunol 1990;20:2577-2583.
95. Conti-Tronconi M, McLane K, Raftery M, Grando S, Pia Protti M: The nicotinic acetycholine receptor: structure and autoimmune pathology. Critical Rev Biochem Mol Biol 1994;29:69-123.
96. Manfredi A, Pia Protti M, Bellone M, Moiola L, Conti-Tronconi B: Molecular anatomy of an autoantigen: T and B epitopes on the nicotinic acetylcholine receptor in myasthenia gravis. J Lab Clin Med 1992;120:13-21.
97. Berrih-Aknin S, Cohen-Kaminsky S, Lepage V, Neumann D, Bach J-F, Fuchs S: T-cell antigenic sites involved in myasthenia gravis: correlations with antibody titre and disease severity. J Autoimmunity 1991;4:137-153.
98. Link H, Olsson O, Sun J, Wang W, Anderson G, Ekre H, Brenner T, Abramsky O, Olsson T: Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls. J Clin Invest 1991;87:2191-2196.
99. Melms A, Malcherek G, Gern U, Wietholter H, Muller C, Schoepfer R, Lindstrom J: T cells from normal and myasthenic indivuals recognize the human acetylcholine receptor: heterogeneity of antigenic sites on the α-subunit. Ann Neurol 1992;31:311-318.
100. Oosterhuis H: Myasthenia gravis. A survey. Clin Neurol Neurosurg 1981;83:105-135.
101. Kirchner T, Schalke B, Melms A, von Kugelgen T, Muller-Hermelink H: Immunological patterns of non-neoplastic changes in the thymus in myasthenia gravis. Virchows Arch B 1986;52:237-257.
102. Sommer N, Willcox N, Harrcourt G, Newsom-Davis J: Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells. Ann Neural 1990;28:312-319.
103. Kirchner T, Tzartos S, Hoppe F, Schalke B, Wekerle H, Muller-Hermeling H: Pathogenesis of myasthenia gravis. Acetylcholine receptor-related antigenic determinants in tumor-free thymuses and thymic epithelial tumors. Am J Pathol 1988;130:268-280.
104. Wakkach A, Guyon T, Bruand C, Tzartos S, Cohen-Kaminski S, Berrih-Aknin S: Expression of acetylcholine receptor genes in human thymic epithelial cells. Implications for myasthenia gravis. J Immunol 1996;157:3752-3760.
105. Garchon H-J, Djabiri F, Viard J-P, Gajdos P, Bach J-F: Involvement of human muscle acetylcholine receptor α-subunit gene (CHRNA) in susceptibility to myasthenia gravis. Proc Natl Acad Sci USA 1994;91:4668-4672.
106. Guyon T, Levasseur P, Truffault F, Cottin C, Gaud C, Berrih-Aknin S: Regulation of acetylcholine receptor a subunit variants RNA in human myasthenia gravis. Quantification of steady-state levels of messenger RNA in muscle biopsy using the polymerase chain reaction. J Clin Invest 1994;94:16-24.
107. Asher O, Neumann D, Fuchs S: Increased levels of acetylcholine receptor α-subunit mRNA in experimental autoimmune myasthenia gravis. FEBS Lett 1988; 233:277-281.
108. Asher O, Neumann D, Witzemenn V, Fuchs S: Acetylcholine receptor gene expression in experimental autoimmune myasthenia gravis. FEBS Lett 1990;267:231-235.
109. Asher O, Provenzano C, Fuchs S: Regulation of acetylcholine receptor gene expression in rats treated with α-bungarotoxin. FEBS 1991; 282:242-246.
110. Asher O, Fuchs S, Zuk D, Rapaport D, Buonanno A: Changes in the expression of mRNAs for myogenic factors and other muscle-specific proteins in experimental autoimmune myasthenia gravis. FEBS 1992;299:15-18.
111. Asher O, Kues W, Witzemann V, Tzartos S, Fuchs, Souroujon M: Increased gene expression of acetylcholine receptor and myogenic factors in passively transferred experimental autoimmune myasthenia gravis. J Immunol 1993;151:6442-6450.
112. Abramsky O, Aharonow A, Teitelbaum D, Fuchs S: Myasthenia gravis and acetylcholine receptor. Effect of steroids in clinical course and cellular immune response to acetylcholine receptor. Arch Neurol 1975;32:684-687.
113. Seybold M, Drachman D: Gradually increasing doses of prednison in myasthenia gravis. N Engl J Med 1974;290:81-84.
114. Kaplan I, Blakely B, Pavlath G, Travis M, Blau H: Steroids induce acetylcholine receptors on cultured human muscle: implications for myasthenia gravis. Proc Natl Acad Sci 1990;87:8101-8104.
115. Matell G: Immunesuppressive drugs: azathioprine in the treatment of myashenia gravis. Ann NY Acad Sci 1987;505:588-594.
116. Michels M, Hohlfeld R, Hartung H-P, Heininger K, Besinger U, Toyka K: Myasthenia gravis: discontinuation of long-term azathioprine. Ann Neurol 1988;24:798 (letter).
117. Cornelio F, Antozzi C, Mantegazza R, Confaloneri P, Berta E, Peluchetti D, Sghirlanzoni A, Fiacchino F: Immunosuppressive treatments. Their efficacy on myasthenia gravis patients' outcome and on the natural course of the disease. Ann NY Acad Sci 1993;681:594-602.
118. Tindall R, Phillips J, Rollins J, Wells L, Hall K: A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci 1993;681:539-551.
119. Samtleben W, Besinger U, Toyka K, Fateh-Moghadam A, Brehm G, Gurland H: Plasma-seperation in myasthenia gravis: a new method of rapid plasma exchange. Klin Wochenschr 1980;58:47-49.
120. Nielsen V, Paulson O, Rosenkvist J, Holsoe E, Lefvert A: Rapid improvement of myasthenia gravis after plasma exchange. Ann Neurol 1982;11:160-169.
121. ul. J Immunol 1992;148:3049-3054.
122. S molecules. J Immunol 1990;145:1687-1693.
123. Smith S, Allen P: Myosin-induced acute myocarditis is a T cell-mediated disease. J Immunol 1991;147: 2141-2147.
124. Wauben M, Hoedemaekers A, Graus Y, Wagenaar J, van Eden W, De Baets M: Inhibition of experimental autoimmune myasthenia gravis by major histocompatibility complex class II competitor peptides results not only in a suppressed but also in an altered immune response. Eur J Immunol 1996;26:2866-2875.
125. Ma C-G, Zhang G-X, Xiao B-G, Wang Z-Y, Link J, Olsson T, Link H: Mucosal tolerance to experimental autoimmune myasthenia gravis is associated with down-regulation of AChR-specific IFN-γ-expressing Th l-like cells and up-regulation of TGF-β mRNA in mononuclear cells. Ann NY Acad Sci 1996;788:273-287.
126. Souroujon M, Pachner A , Fuchs S: The treatment of passively transferred experimental myasthenia with anti-idiotypic antibodies. Neurology 1986;36:622-625.
127. Araga S, Blalock J: Use of complementary peptides and their antibodies in B-cell-mediated autoimmune disease: prevention of experimental autoimmune myasthenia gravis with a peptide vaccine. Immunomethods 1994;5: 130-135.
128. Verschuuren JJGM, Graus YMF, van Breda Vriesman PJC, Tzartos S, De Baets MH: In vivo effects of neonatal administration of antiidiotype antibodies on experimental autoimmune myasthenia gravis. Autoimmunity 1991;10: 173-179.
129. Toyka K, Lowenadler B, Heiniger K, Besinger U, Birnberge K, Fateh-Moghadam A, Heilbronn E: Passively transferred myasthenia gravis: protection of mouse endplates by Fab fragments from human myasthenic IgG. J Neurol Neurosurg Psychiatry 1980;43: 836-840.
130. Mamalaki A, Trakas N , Tzartos S: Bacterial expression of a single-chain Fv fragment which efficiently protects the acetylcholine receptor against antigenic modulation caused by myasthenic antibodies. Eur J Immunol 1993;23:1839-1845.
131. Graus Y, De Baets M, Parren P, Berrih-Aknin S, Wokke J, van Breda Vriesman P, Burton D: Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymusderived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies. J Immunol 1997;158:1919-1929.